Comparative Pharmacology
Head-to-head clinical analysis: SAXENDA versus VICTOZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SAXENDA versus VICTOZA.
SAXENDA vs VICTOZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that increases insulin secretion, decreases glucagon secretion, delays gastric emptying, and promotes satiety via central GLP-1 receptor activation.
Glucagon-like peptide-1 (GLP-1) receptor agonist; increases insulin secretion, decreases glucagon secretion, slows gastric emptying, and promotes satiety.
Subcutaneous injection once daily, starting at 0.6 mg and titrating weekly by 0.6 mg increments to a maintenance dose of 3.0 mg.
Subcutaneous injection: 0.6 mg once daily for 1 week, then increase to 1.2 mg once daily. May further increase to 1.8 mg once daily if needed for glycemic control.
None Documented
None Documented
11–13 hours (subcutaneous). Steady-state is reached after 3–5 once-daily doses.
After subcutaneous administration, the terminal elimination half-life is approximately 13 hours, supporting once-daily dosing.
Renal excretion of intact liraglutide is minimal; approximately 6% is excreted as intact liraglutide in urine. The remainder is metabolized and eliminated via the kidneys and feces, with no single metabolite accounting for >10% of the dose.
Liraglutide is eliminated via degradation by general proteolysis and not by specific enzymes; the intact drug is not excreted in urine or feces. Degraded metabolites are excreted via urine and feces.
Category C
Category C
GLP-1 Receptor Agonist, Anti-obesity
GLP-1 Receptor Agonist